Ovarian Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), By Diagnosis (Imaging, Blood Test, Biopsy), By End-use, By Region, And Segment Forecasts, 2025 - 2033

Ovarian Cancer Diagnostics Market Summary

The global ovarian cancer diagnostics market size was estimated at USD 1.74 billion in 2024 and is projected to reach USD 3.11 billion by 2033, growing at a CAGR of 6.73% from 2025 to 2033. The ovarian cancer diagnostics market is advancing rapidly, driven by biomarker discovery, federal funding, and new technologies.

In 2025, the U.S. will see nearly 21,000 new cases and over 12,000 deaths, underscoring the need for earlier detection. Breakthroughs include PPP2R1A mutations as predictive biomarkers in ovarian clear cell carcinoma and AOA Dx’s multi-omic, AI-powered blood test, which achieved >90% accuracy in symptomatic women, outperforming traditional biomarkers. Federal support is strong, with the DoD allocating $650M in FY25 to the Ovarian Cancer Research Program, funding precision medicine, prevention, and survivorship studies. Despite progress, testing disparities persist, particularly in older and underserved women. Overall, the market is shifting toward precision, multi-omic, and patient-centric diagnostics with significant growth potential.

The ovarian cancer diagnostics market is significantly transforming, shaped by epidemiological need, biomarker discovery, technological innovation, and shifting clinical strategies. In 2025, an estimated 20,890 new cases of ovarian cancer will be diagnosed in the U.S., with 12,730 deaths (American Cancer Society). Despite being the 11th most common cancer among women, ovarian cancer remains the fifth leading cause of cancer-related death and the deadliest gynecologic malignancy. As of 2022, approximately 243,572 women in the U.S. were living with a prior ovarian cancer diagnosis (SEER), reflecting the growing patient base that depends on early and accurate diagnostics. Significantly, mortality rates are modestly declining but lag behind improvements seen in other cancers, highlighting the urgency for better detection and stratification tools.

The market is increasingly shaped by biomarker-driven innovation. A landmark discovery in July 2025 at MD Anderson Cancer Center identified PPP2R1A mutations as a predictive biomarker for improved survival in ovarian clear cell carcinoma (OCCC) treated with immunotherapy, with median overall survival extending to 66.9 months versus 9.2 months in non-mutant patients. This breakthrough validates immunogenomic diagnostics and highlights the role of genetic testing in patient stratification, fueling demand for next-generation molecular diagnostics. Parallel efforts focus on the PP2A pathway, with early-phase trials exploring therapeutic targeting in OCCC and other tumor types, demonstrating how diagnostics and therapeutics converge in a precision oncology framework.

In parallel, large-scale funding initiatives are reinforcing this momentum. In April 2025, the U.S. Department of Defense (DoD) announced $650 million in appropriations for its Congressionally Directed Medical Research Programs (CDMRP), with a dedicated portion for the Ovarian Cancer Research Program (OCRP). The FY25 OCRP will support high-impact research on early detection, prevention, survivorship, and precision medicine, offering major grants such as the Investigator-Initiated Research Award (up to $1.05M), the Clinical Trial Academy - Early Career Investigator Award (up to $1.4M), and Pilot Awards (up to $350K). These investments signal strong federal backing to accelerate diagnostic innovation and improve clinical outcomes.

Despite advances, testing gaps remain a significant market driver. In March 2025, the Ovarian Cancer Research Alliance (OCRA) and Komodo Health reported that nearly half of women with ovarian cancer are not receiving genetic testing, despite universal guidelines. Disparities are most evident among women over 65 and those on public insurance, where testing rates fall below 40%. Since genetic testing underpins therapy selection particularly for BRCA mutation-positive patients eligible for PARP inhibitors addressing these gaps is central to improving outcomes. As a result, organizations like OCRA are expanding patient-support tools, such as the “Find a Doctor” platform (launched April 2024), which connects patients to more than 2,000 gynecologic oncology specialists and integrates trial-finder functionality, increasing awareness and adoption of diagnostics.

The market also benefits from strategic realignment in preventive strategies. Following evidence from large-scale UK trials showing the limited impact of symptom-based detection on mortality, OCRA and the Society of Gynecologic Oncology (SGO) began advocating for universal genetic testing and opportunistic salpingectomy (fallopian tube removal during pelvic surgery) in 2023. This shift reflects a growing reliance on risk-based and genetic diagnostics rather than conventional screening, driving greater uptake of molecular and genomic tests.

Technological breakthroughs are also redefining early detection. In August 2025, AOA Dx published peer-reviewed results in Cancer Research Communications showing that its multi-omic, AI-powered blood test achieved strong accuracy in symptomatic women, with an AUC of 93% for all stages and 91% for early-stage ovarian cancer in training cohorts, and 92% and 88% respectively, in independent real-world cohorts. The platform outperformed traditional biomarkers by combining lipid, ganglioside, and protein biomarkers with machine learning, offering a scalable, non-invasive solution that could transform early-stage detection, where survival benefits are most significant.

Furthermore, initiatives such as OCRA’s international data commons and the first ovarian ad endometrial cancer registry (2023) create the infrastructure for large-scale real-world evidence generation. By consolidating patient-level genomic and clinical data, these efforts aim to accelerate biomarker discovery, improve predictive diagnostics, and inform payor adoption an increasingly important growth lever for the diagnostics industry.

Overall, the ovarian cancer diagnostics market moves rapidly from traditional pathology and symptom awareness toward a genomics-led, precision-driven, patient-centered model. Growth is fueled by a convergence of factors: rising disease prevalence, breakthrough biomarkers such as PPP2R1A, demand for equitable access to genetic testing, integration of digital patient navigation tools, robust federal research funding, and international collaboration in data-driven research. While challenges around testing disparities, cost barriers, and lack of validated early screening tools persist, the sector is evolving into a high-value segment of the broader next-generation cancer diagnostics market. Its trajectory is increasingly defined by companion diagnostics, liquid biopsy innovations, and immunogenomic testing, which are expected to unlock significant commercial and clinical opportunities over the next decade.

Global Ovarian Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ovarian cancer diagnostics market report based on cancer, diagnosis, end-use, and region:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Epithelial Tumor
• Germ Cell Tumor
• Stromal Cell Tumor
• Others
• Diagnosis Outlook (Revenue, USD Million, 2021 - 2033)
• Imaging
• Ultrasound
• CT Scan
• MRI Scan
• PET Scan
• Others
• Blood Test
• CA125
• HER2
• BRCA
• CEA
• ER & PR
• KRAS Mutation
• Others
• Biopsy
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Laboratories
• Cancer Diagnostic Centers
• Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• UAE
• South Arabia
• South Africa
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more